Grant Avenue Capital
Grant Avenue Capital focuses on healthcare services, pharma services, medtech, and healthcare IT. Its stated target range is $5 million to $30 million in EBITDA, with transaction structures that include majority and minority recapitalizations, buyouts, corporate carve-outs, buy-and-builds, and special situations.
What stands out about Grant Avenue Capital
Grant Avenue Capital publicly targets healthcare businesses with $5 million to $30 million in EBITDA and evaluates forward-thinking management teams, attractive market dynamics, defined customer value propositions, and multiple growth levers. It states that it provides flexible capital and operational support across areas including M&A, technology, human capital, sales and marketing, service-line expansion, and de novo initiatives.[1][2][3][4]
What does Grant Avenue Capital invest in?
Grant Avenue Capital is a healthcare-focused private equity firm founded in 2019 and headquartered at 437 Madison Ave., Suite #1901, New York, NY 10022. The website identifies Grant Avenue Capital LLC and its affiliates as the entities operating the site.
The SEC Investment Adviser Public Disclosure system identifies Grant Avenue Capital LLC as an SEC-registered investment adviser with CRD #313104 and SEC file number 801-126247. The listed SEC registration effective date is July 29, 2022.[1][2][7]
Grant Avenue Capital states that it provides flexible capital and operational support to portfolio companies. Its support areas include human capital, sales and marketing, technology enablement, service-line expansion, M&A, and de novo initiatives.
The firm focuses on private-company recapitalizations, buyouts, corporate carve-outs, buy-and-builds, and special situations, including founder-owned businesses and majority or minority recapitalizations.[3]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
Published criteria: Grant Avenue Capital targets companies with $5 million to $30 million in EBITDA and seeks forward-thinking management teams, attractive market dynamics, a defined customer value proposition, and multiple growth levers.[4]
What should a business owner evaluate before considering a transaction with Grant Avenue Capital?
For an owner evaluating Grant Avenue Capital, the published parameters identify a healthcare mandate, a $5 million to $30 million EBITDA target, flexible majority and minority recapitalization structures, and support areas that include M&A, talent, technology, sales and marketing, service-line expansion, and de novo initiatives.
The About page does not state a fund size or standard equity-check range. An owner should clarify the proposed ownership structure, founder liquidity and rollover terms, governance rights, leverage, acquisition funding, management incentives, operating resources, fees, transaction expenses, and the firm’s expected investment horizon and exit-planning process.[3][4]
What equity-check range and fund capacity would apply to a new platform investment
Does Grant Avenue Capital require majority control, or are minority investments currently available
How would the firm structure founder liquidity, rollover equity, management incentives, governance, and decision rights
What companies does Grant Avenue Capital target?
Grant Avenue Capital targets companies with $5 million to $30 million in EBITDA. It seeks forward-thinking management teams, attractive market dynamics, a defined customer value proposition, and multiple growth levers.[4]
Grant Avenue Capital targets healthcare services, pharma services, medtech, and healthcare IT businesses.[4]
The firm’s official portfolio descriptions include companies operating across the United States, nationwide, or across the US.[5]
Grant Avenue Capital’s stated transaction structures include buy-and-builds, along with private-company recapitalizations, buyouts, corporate carve-outs, and special situations.[3]
The official portfolio page identifies current investments including H2 Health, Fortis Home Health and Hospice, Ovation Healthcare, Helios Clinical Research, Performance Home Medical, CREO, PatientCare EMS, 21st Century Healthcare, and School of EMS.
The Terms of Use states that the current and previous portfolio companies listed on the site are not a complete list of all investments historically made by Grant Avenue.[2][5]
Grant Avenue Capital announced the acquisition of PatientCare EMS Solutions on January 7, 2026, and announced the acquisition of 21st Century Healthcare on January 21, 2026. It also announced a partnership with The School of EMS on July 7, 2026.[6]
What is not clear from Grant Avenue Capital's public investment criteria?
The About page states the $5 million to $30 million EBITDA target but does not state a fund size, standard equity-check range, minimum investment amount, or maximum investment amount.
The Terms of Use states that the current and previous portfolio companies listed on the site are not a complete list of all investments historically made by Grant Avenue.[2][4]
Questions to ask when evaluating Grant Avenue Capital as a buyer or investment partner
What equity-check range and fund capacity would apply to a new platform investment?
Does Grant Avenue Capital require majority control, or are minority investments currently available?
How would the firm structure founder liquidity, rollover equity, management incentives, governance, and decision rights?
What leverage levels and acquisition-funding resources would be available for a buy-and-build?
How does Grant Avenue Capital define its expected investment horizon and exit-planning process for a new platform?
Which operating resources would be assigned to the company, and what fees or transaction expenses would apply?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Services / capabilities
- Industry / market focus
- Geography / market coverage
- Transaction / portfolio evidence
- SEC investment adviser record
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.